[go: up one dir, main page]

MX2022001433A - Tratamiento personalizado de enfermedades oftalmologicas. - Google Patents

Tratamiento personalizado de enfermedades oftalmologicas.

Info

Publication number
MX2022001433A
MX2022001433A MX2022001433A MX2022001433A MX2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A MX 2022001433 A MX2022001433 A MX 2022001433A
Authority
MX
Mexico
Prior art keywords
amd
personalized treatment
ophthalmologic diseases
macular edema
treatment
Prior art date
Application number
MX2022001433A
Other languages
English (en)
Inventor
Robert James Weikert
Aaron Osborne
Hugh Lin
David Andrew Silverman
Jeffrey R Willis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022001433A publication Critical patent/MX2022001433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Primary Health Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a VEGF y ANG2 para su uso en el tratamiento de enfermedades vasculares oculares, tales como AMD neovascular (nAMD) (también conocida como neovascularización coroidea [CNV] secundaria a la degeneración macular relacionada con la edad [AMD] o AMD húmeda), retinopatía diabética, en particular, edema macular diabético (DME) o edema macular secundario a la oclusión de la vena retiniana (RVO).
MX2022001433A 2019-08-06 2020-08-06 Tratamiento personalizado de enfermedades oftalmologicas. MX2022001433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883499P 2019-08-06 2019-08-06
PCT/EP2020/072088 WO2021023804A1 (en) 2019-08-06 2020-08-06 Personalized treatment of ophthalmologic diseases

Publications (1)

Publication Number Publication Date
MX2022001433A true MX2022001433A (es) 2022-02-22

Family

ID=72193416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001433A MX2022001433A (es) 2019-08-06 2020-08-06 Tratamiento personalizado de enfermedades oftalmologicas.

Country Status (11)

Country Link
US (1) US20220162296A1 (es)
EP (1) EP4010370A1 (es)
JP (3) JP7403553B2 (es)
KR (1) KR20220031666A (es)
CN (4) CN119367533A (es)
AU (1) AU2020326243A1 (es)
CA (1) CA3145239A1 (es)
IL (1) IL289405A (es)
MX (1) MX2022001433A (es)
TW (3) TW202528344A (es)
WO (1) WO2021023804A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948760A (zh) 2018-05-10 2024-11-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
JP7689838B2 (ja) * 2021-03-04 2025-06-09 住友化学株式会社 欠陥検査方法及び欠陥検査装置
JP2024512701A (ja) * 2021-03-30 2024-03-19 アブプロ コーポレーション 抗ａｎｇ２×ｖｅｇｆ多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法
JP2024516541A (ja) * 2021-04-07 2024-04-16 ジェネンテック， インコーポレイテッド ベースライン特性を使用する血管新生型加齢黄斑変性に対する処置予後予測
EP4449428A1 (en) * 2021-12-17 2024-10-23 Genentech Inc. Predicting optimal treatment regimen for neovascular age-related macular degeneration (namd) patients using machine learning
JP2023135646A (ja) * 2022-03-15 2023-09-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生性眼障害の処置のための長期高用量ｖｅｇｆアンタゴニストレジメン
CN119365206A (zh) * 2022-03-15 2025-01-24 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
CN116738352B (zh) * 2023-08-14 2023-12-22 武汉大学人民医院（湖北省人民医院） 视网膜血管阻塞疾病的视杆细胞异常分类方法及装置
WO2026010945A1 (en) * 2024-07-04 2026-01-08 Genentech, Inc. Zifibancimig for use in methods for treating ocular diseases
WO2026010946A1 (en) * 2024-07-04 2026-01-08 Genentech, Inc. Zifibancimig for use in methods for treating ocular diseases via an ocular implant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
ES2774972T3 (es) * 2011-10-13 2020-07-23 Aerpio Therapeutics Inc Tratamiento de enfermedades oculares
DK3495387T3 (da) * 2012-07-13 2021-11-08 Roche Glycart Ag Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
JP6618893B2 (ja) * 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法
PE20151807A1 (es) * 2013-04-29 2015-12-02 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
JP2019504402A (ja) * 2015-12-18 2019-02-14 コグノア， インコーポレイテッド デジタル個別化医療のためのプラットフォームおよびシステム
MX2019011141A (es) * 2017-03-22 2019-11-05 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
EP3749359A1 (en) * 2018-02-06 2020-12-16 F. Hoffmann-La Roche AG Treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
TW202120543A (zh) 2021-06-01
CA3145239A1 (en) 2021-02-11
AU2020326243A1 (en) 2022-02-17
CN119367533A (zh) 2025-01-28
EP4010370A1 (en) 2022-06-15
TW202528344A (zh) 2025-07-16
TWI881273B (zh) 2025-04-21
JP7403553B2 (ja) 2023-12-22
TWI785360B (zh) 2022-12-01
CN114341177B (zh) 2025-02-11
JP2025060771A (ja) 2025-04-10
US20220162296A1 (en) 2022-05-26
CN119868538A (zh) 2025-04-25
JP2022534351A (ja) 2022-07-29
CN114341177A (zh) 2022-04-12
TW202317613A (zh) 2023-05-01
KR20220031666A (ko) 2022-03-11
CN119303075A (zh) 2025-01-14
JP2023123741A (ja) 2023-09-05
IL289405A (en) 2022-02-01
WO2021023804A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
MX2022001433A (es) Tratamiento personalizado de enfermedades oftalmologicas.
MY176514A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX385629B (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
EP4477233A3 (en) A stable liquid formulation of fusion protein with igg fc domain
PH12014500220A1 (en) Anti-vegf single variable domains fused to fc domains
RU2014129316A (ru) Способы ингибирования глазного ангиогенеза
HK1201438A1 (en) Treatment of ocular disease
WO2014031429A3 (en) Liposome formulations
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
MX2020010968A (es) Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
MX2018000869A (es) Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
ZA202204939B (en) Compounds for treatment of eye diseases associated with excessive vascularisation
RU2017133101A (ru) Пептиды для ингибирования ангиогенеза
JP2018508528A5 (es)
MY199462A (en) Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2006039252A3 (en) Compositions and methods for treating ophthalmic diseases
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
Matsubara Aflibercept/ranibizumab
HK1189820A (en) Use of a vegf antagonist to treat angiogenic eye disorders
Casati Increased introcular pressure, retinal and vitreous haemorrhage leading to decreased visual acuity caused by device malfunction: case report
NANGREJO et al. SHORT TERM COMPLICATIONS OF INTRAVITREAL INJECTION OF BEVACIZUMAB.
Semeraro Acute uveitis following intravitreal administration in elderly patients: 4 case reports
Orssaud Urrets-Zavalia syndrome as a complication of ocular hypotonia and bilateral anterior uveitis: case report